Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00608153

Purpose

The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.

Condition
Essential Hypertension

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Hydrochlorothiazide Candesartan cilexetil CV 11974

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

To estimate under naturalistic conditions the compliance rate, defined as the number of subjects with regular intake of the prescribed dose of candesartan or candesartan/HCT as judged by the physician at the end of the observational period. [ Time Frame: app. 3 monthly ]

Secondary Outcome Measures:

To assess under naturalistic conditions the subject's reason(s) for being compliant or non-compliant with the intake of the pre-scribed dose of candesartan or candesartan/HCT [ Time Frame: app. 3 monthly ]
To assess under naturalistic conditions the subject's reason(s) for withdrawal of the pre-scribed dose of candesartan or candesartan/HCT [ Time Frame: app. 3 monthly ]
To assess under naturalistic conditions whether physicians are using procedures to improve the subject's compliance regarding the intake of candesartan or candesartan/HCT and to get insight in the type and effects of these procedures [ Time Frame: app. 3 monthly ]

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	1773
Study Start Date:	January 2007
Study Completion Date:	September 2007

Groups/Cohorts
1 Patient with essential hypertension under treatment with candesartan or candesartan HCT

Eligibility

Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

primary care ambulant patient

Criteria

Inclusion Criteria:

essential hypertension
under candesartan treatment

Exclusion Criteria:

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00608153

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:	R. E. Schmieder, MD	University hospital Erlangen-Nurnberg
Study Chair:	Andrea Pahor, MD	MED Dep., AstraZeneca Germany

More Information

Responsible Party:	AstraZeneca Germany ( Andrea Pahor )
Study ID Numbers:	NIS-CGE-ATA-2007/1
Study First Received:	January 23, 2008
Last Updated:	February 5, 2008
ClinicalTrials.gov Identifier:	NCT00608153
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:

essential hypertension
ARB
compliance
candesartan

Study placed in the following topic categories:

Candesartan cilexetil
Candesartan
Vascular Diseases
Essential hypertension

Angiotensin II
Hydrochlorothiazide
Hypertension

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Therapeutic Uses
Sodium Chloride Symporter Inhibitors

Physiological Effects of Drugs
Diuretics
Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009